神經刺激產品的美國市場 是由出版商Medtech Insight在2010年03月所出版的。
這份英文市場調查報告書包含228 Pages ? 58 Exhibits 價格從美金4750起跳。
美國神經刺激設備市場因高齡化以及與年齡有關的神經疾病患者的增加，預估在今後10年間將會有顯著的成長。2009年美國植入式神經刺激產品市場有12億2,770億美金之多，市場規模預估將在2014年超過26億美金。
本報告除概略介紹神經系統及主要神經疾病之外，如經皮末梢神經電子刺激器等神經刺激產品市場概要、參與企業概況等內容亦整理摘記如下。
實施概要
第一章 神經系統概要與主要神經疾病
- 神經系統
- 神經及其他疾病
- 阿滋海默症
- 憂鬱症
- 癲癇
- 胃輕癱
- 肥胖
- 失禁
- 疼痛
- 帕金森氏症
- 其他
第二章 神經刺激產品
- 植入式神經刺激產品
- 適用植入式神經刺激產品之主要治療領域
- 重度憂鬱症
- 癲癇
- 胃輕癱
- 聽力損失
- 失禁
- 疼痛
- 肌張力不全症、原發性顫抖症、帕金森氏症
- 失眠症
- 新興應用領域
- 市場預測
- 競合分析
第三章 經皮末梢神經電子刺激器
企業簡介
- Advanced Bionics Corporation/Sonova Holding AG
- Apnex Medical, Inc.
- BioMedical Life Systems, Inc.
- Boston Scientific Corporation
- Cochlear LTD
- Cyberonics, Inc.
- DJO, Inc.
- Dynatronics Corporation
- EnteroMedics, Inc.
- MED-EL Corporation
- Medtronic, Inc.
- RS Medical, Inc.
- Second Sight Medical Products, Inc.
- St. Jude Medical, Inc.
附錄：企業清單
Abstract
One of the most promising medical device markets to date is neurostimulation.
This newest report from Medtech Insight includes analyses of products,
markets, competitors, and opportunities in the United States (U.S.)
neurostimulation products market. This market, as defined in this report,
includes several types of implantable neurostimulation devices including
cochlear implants and systems for deep brain stimulation, gastric nerve
stimulation, sacral nerve stimulation, spinal cord stimulation, and vagus
nerve stimulation.
Neurostimulation currently treats several debilitating conditions including
chronic pain, epilepsy, essential tremor and dystonia, gastroparesis, hearing
loss, incontinence, major treatment-resistant depression, obsessive-compulsive
disorder, and Parkinson' s disease. Emerging and exciting areas of development
include the treatment of large-population diseases and disorders including
Alzheimer' s disease, blindness, chronic migraines, morbid obesity, obstructive
sleep apnea, paralysis, stroke, and tinnitus, with the potential to expand to
several other applications.
In addition to implantable neurostimulation systems and transcutaneous
electrical nerve stimulators (TENS), this report from Medtech Insight includes
analyses of transcranial magnetic nerve stimulation systems and other
noninvasive electrical nerve stimulators. In addition, incidence and procedure
numbers are provided for some of the most common major neurologic diseases and
disorders.
The U.S. neurostimulation products market is poised for significant growth
over the next decade due to factors such as the aging population, growth in
age-related neurologic diseases and disorders, and the need for effective,
alternative therapies. In 2009, the U.S. market for implantable
neurostimulation products was estimated at $1,227.7 million; this market is
expected to grow at a compound annual rate of 16.3% during the forecast period
covered by this report, reaching more than $2.6 billion in the year 2014. At
the same time, the market for TENS is projected to grow at a compound annual
rate of 8.3%, reaching an estimated $113.8 million in the year 2014.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary
and secondary research among the clinicians, researchers, and competitors in
the marketplace, and draw upon the industry expertise of a network of industry
insiders. Medtech Insight exhaustively corroborates the data as a baseline for
completing forward-looking analysis and providing insight into product,
technology and market evolution.
Report Statistics
- 228 Pages
- 58 Exhibits
- 14 Company Profiles
Table of Contents
Executive Summary
- i. Implantable Neurostimulation Products
- ii. Transcutaneous Electrical Nerve Stimulation Products
- iii. Methodology
- Exhibit ES-1: Selected Neurologic Conditions, Prevalence and Potential
Neurostimulation Patient Population
- Exhibit ES-2: Neurostimulation Products, Combined Market Forecast,
2009-2014
- Exhibit ES-3: 2009, Neurostimulation Products Market, Estimated Percentage
of Sales, by Application
- Exhibit ES-4: Neurostimulation Products (Including Cochlear Implants),
Market Forecast, 2009-2014
- Exhibit ES-5: Transcutaneous Electrical Nerve Stimulators, Market
Forecast, 2009-2014
1. OVERVIEW OF THE NERVOUS SYSTEM AND selected neurologic diseases/DISORDERS
- 1.1 The Nervous System
- 1.1.1 Sacral Nerves
- 1.1.2 Vagus Nerves
- 1.1.3 Neurons
- 1.1.4 Brain
- 1.1.5 Spine
- 1.2 Neurologic and Other Diseases/Disorders
- 1.2.1 Alzheimer' s Disease
- 1.2.1.1 Etiology
- 1.2.1.2 Incidence
- 1.2.1.3 Prevalence
- 1.2.1.4 Treatment Options
- 1.2.1.4.1 Drug Therapy
- 1.2.1.4.2 Neurostimulation and Other Device-Based Therapies
- 1.2.1.4.3 Surgery
- 1.2.1.4.4 Prevention
- 1.2.2 Depression
- 1.2.2.1 Etiology
- 1.2.2.2 Incidence
- 1.2.2.3 Prevalence
- 1.2.2.4 Treatment Options
- 1.2.2.4.1 Drug Therapy
- 1.2.2.4.2 Neurostimulation
- 1.2.2.5 Prevention
- 1.2.3 Epilepsy
- 1.2.3.1 Etiology
- 1.2.3.2 Incidence
- 1.2.3.3 Prevalence
- 1.2.3.4 Treatment Options
- 1.2.3.4.1 Drug Therapy
- 1.2.3.4.2 Neurostimulation
- 1.2.3.4.3 Surgery
- 1.2.3.4.4 Prevention
- 1.2.4 Gastroparesis
- 1.2.4.1 Etiology
- 1.2.4.2 Incidence
- 1.2.4.3 Prevalence
- 1.2.4.4 Treatment Options
- 1.2.4.4.1 Drug Therapy
- 1.2.4.4.2 Neurostimulation
- 1.2.4.4.3 Surgery
- 1.2.4.4.4 Prevention
- 1.2.5 Obesity
- 1.2.5.1 Etiology
- 1.2.5.2 Incidence
- 1.2.5.3 Prevalence
- 1.2.5.4 Treatment Options
- 1.2.5.4.1 Drug Therapy
- 1.2.5.4.2 Neurostimulation
- 1.2.5.4.3 Surgery
- 1.2.5.4.4 Prevention
- 1.2.6 Incontinence
- 1.2.6.1 Etiology
- 1.2.6.2 Incidence
- 1.2.6.3 Prevalence
- 1.2.6.4 Treatment Options
- 1.2.6.4.1 Drug Therapy
- 1.2.6.4.2 Neurostimulation
- 1.2.6.4.3 Surgery
- 1.2.6.4.4 Prevention
- 1.2.7 Pain
- 1.2.7.1 Nociceptive Pain
- 1.2.7.2 Neuropathic Pain
- 1.2.7.3 Acute Pain
- 1.2.7.3.1 Etiology
- 1.2.7.3.2 Incidence
- 1.2.7.3.3 Prevalence
- 1.2.7.3.4 Treatment Options
- 1.2.7.3.4.1 Neurostimulation
- 1.2.7.4 Chronic Pain
- 1.2.7.4.1 Etiology
- 1.2.7.4.2 Incidence
- 1.2.7.4.3 Prevalence
- 1.2.7.4.4 Treatment Options
- 1.2.7.4.4.1 Drug Therapy
- 1.2.7.4.4.2 Neurostimulation and Other Device-Based Therapies
- 1.2.7.4.4.3 Alternative Therapies
- 1.2.7.4.5 Chronic Migraine
- 1.2.7.4.5.1 Neurostimulation
- 1.2.8 Parkinson' s Disease
- 1.2.8.1 Etiology
- 1.2.8.2 Incidence
- 1.2.8.3 Prevalence
- 1.2.8.4 Treatment Options
- 1.2.8.4.1 Drug Therapy
- 1.2.8.4.2 Neurostimulation
- 1.2.8.4.3 Surgery
- 1.2.8.4.4 Prevention
- 1.2.9 Other Neurologic Diseases/Disorders
- Exhibit 1-1: United States Population, by Age Group, Selected Years,
2000-2050
- Exhibit 1-2: Selected Neurologic Conditions, Prevalence and Potential
Neurostimulation Patient Population
- Exhibit 1-3: The Sacral Nervous System
- Exhibit 1-4: The Vagus Nerve
- Exhibit 1-5: Anatomy of the Brain
- Exhibit 1-6: Anatomy of the Spine
- Exhibit 1-7: Alzheimer' s Disease, Facts and Figures
- Exhibit 1-8: 2010, Alzheimer' s Disease Medications
- Exhibit 1-9: Depression, Facts and Figures
- Exhibit 1-10: Epilepsy, Facts and Figures
- Exhibit 1-11: Gastroparesis, Facts and Figures
- Exhibit 1-12: 2010, Obesity Comorbidities
- Exhibit 1-13: Obesity, Facts and Figures
- Exhibit 1-14: Urinary Incontinence, Facts and Figures
- Exhibit 1-15: 2010, Treatment Options for Urinary Incontinence
- Exhibit 1-16: Acute Pain, Facts and Figures
- Exhibit 1-17: Chronic Pain, Facts and Figures
- Exhibit 1-18: Migraine Headache, Facts and Figures
- Exhibit 1-19: Parkinson' s Disease, Facts and Figures
- Exhibit 1-20: Essential Tremor, Facts and Figures
- Exhibit 1-21: Obsessive-Compulsive Disorder, Facts and Figures
- Exhibit 1-22: Stroke, Facts and Figures
- Exhibit 1-23: Obstructive Sleep Apnea, Facts and Figures
- Exhibit 1-24: Tinnitus, Facts and Figures
2. NEUROSTIMULATION PRODUCTS MARKET
- 2.1 Implantable Neurostimulators
- 2.1.1 Cortical Stimulators
- 2.1.2 Deep Brain Stimulators
- 2.1.3 Gastric Nerve Stimulators
- 2.1.4 Sacral Nerve Stimulators
- 2.1.5 Spinal Cord Stimulators
- 2.1.6 Vagus Nerve Stimulators
- 2.1.7 Cochlear Implants
- 2.1.8 Hypoglossal Nerve Stimulators
- 2.1.9 Phrenic Nerve Stimulators
- 2.2 Core Treatment Areas for Implantable Neurostimulators
- 2.2.1 Major Depression
- 2.2.1.1 Cyberonics
- 2.2.1.2 Medtronic
- 2.2.1.3 Northstar Neuroscience
- 2.2.1.4 St. Jude Medical
- 2.2.2 Epilepsy
- 2.2.2.1 Cyberonics
- 2.2.2.2 Integra LifeSciences
- 2.2.2.3 Medtronic
- 2.2.2.4 NeuroPace
- 2.2.2.5 NeuroVista
- 2.2.2.6 Victhom Human Bionics
- 2.2.3 Gastroparesis
- 2.2.4 Hearing Loss
- 2.2.4.1 Advanced Bionics/Sonova Holding
- 2.2.4.2 Cochlear
- 2.2.4.3 MED-EL
- 2.2.5 Incontinence
- 2.2.6 Pain
- 2.2.6.1 Boston Scientific
- 2.2.6.2 Medtronic
- 2.2.6.3 MicroTransponder
- 2.2.6.4 St. Jude Medical
- 2.2.7 Dystonia, Essential Tremor, and Parkinson' s Disease
- 2.2.7.1 Medtrode
- 2.2.7.2 Medtronic
- 2.2.7.3 NeuroMEDx
- 2.2.7.4 St. Jude Medical
- 2.2.8 Sleep Apnea
- 2.2.8.1 Apnex Medical
- 2.2.8.2 Avery Biomedical Devices
- 2.2.8.3 Cardiac Concepts
- 2.2.8.4 ImThera Medical
- 2.2.8.5 Inspire Medical Systems
- 2.2.8.6 Synapse Biomedical
- 2.2.8.7 Victhom Human Bionics
- 2.3 Emerging Applications for Neurostimulation
- 2.3.1 Alzheimer' s Disease
- 2.3.2 Blindness
- 2.3.2.1 Second Sight Medical Products
- 2.3.3 Chronic Headache
- 2.3.3.1 Boston Scientific
- 2.3.3.2 Medtronic
- 2.3.3.3 St. Jude Medical
- 2.3.4 Obesity
- 2.3.4.1 EnteroMedics
- 2.3.4.2 IntraPace
- 2.3.4.3 Johnson & Johnson
- 2.3.4.4 Leptos Biomedical
- 2.3.4.5 Medtronic
- 2.3.4.6 MetaCure
- 2.3.5 Obsessive-Compulsive Disorder
- 2.3.6 Stroke
- 2.3.6.1 Cyberonics
- 2.3.6.2 Northstar Neuroscience
- 2.3.7 Paralysis/Spinal Cord Injury
- 2.3.7.1 The BrainGate Company
- 2.3.7.2 NeuroMetrix
- 2.3.7.3 Ossur with Victhom Human Bionics
- 2.3.7.4 Neurostream Technologies/Otto Bock HealthCare and Victhom
Human Bionics
- 2.3.8 Tinnitus
- 2.3.8.1 Silere Medical Technology
- 2.4 Market Forecast
- 2.5 Competitive Analysis
- Exhibit 2-1: 2010, Selected Advantages and Disadvantages of
Neurostimulation Therapy
- Exhibit 2-2: 2009, Patients Who Have Received Neurostimulation Implants,
by Selected Neurologic Condition
- Exhibit 2-3: 2010, Established Neurostimulation Therapies and Leading
Suppliers
- Exhibit 2-4: Deep Brain Stimulation
- Exhibit 2-5: Neurostimulation in Suppressing Epileptic Seizures;
NeuroPace' s Responsive Neurostimulator Therapy
- Exhibit 2-6: Neurostimulation in the Treatment of Gastroparesis,
Medtronic' s Enterra
- Exhibit 2-7: Cochlear' s Nucleus Freedom Implant
- Exhibit 2-8: Medtronic' s InterStim Therapy System
- Exhibit 2-9: Medtronic' s Neurostimulators for the Treatment of Chronic Pain
- Exhibit 2-10: St. Jude Medical' s Neurostimulators for the Treatment of
Chronic Pain
- Exhibit 2-11: Medtronic' s Activa Therapy for Parkinson' s Disease and
Essential Tremor
- Exhibit 2-12: 2010, Selected Current and Emerging Neurostimulation Systems
- Exhibit 2-13: Second Sight Medical Products' Intraocular Retinal Prosthesis
- Exhibit 2-14: 2009, Neurostimulation Products Market, Estimated Percentage
of Sales, by Application
- Exhibit 2-15: Neurostimulation Products, Selected Market Drivers and
Limiters
- Exhibit 2-16: Neurostimulation Products (Including Cochlear Implants),
Market Forecast, 2009-2014
- Exhibit 2-17: Neurostimulation Products (Excluding Cochlear Implants),
Market Forecast, 2009-2014
- Exhibit 2-18: Cochlear Implants, Market Forecast, 2009-2014
- Exhibit 2-19: 2009, Neurostimulation Products Market (Including Cochlear
Implants), Share by Supplier
- Exhibit 2-20: 2009, Neurostimulation Products Market (Excluding Cochlear
Implants), Share by Supplier
- Exhibit 2-21: 2009, Cochlear Implants Market, Share by Supplier
3. Transcutaneous electrical nerve stimulation products market
- 3.1 Overview
- 3.1.1 Products
- 3.1.1.1 American Imex
- 3.1.1.2 BioMedical Life Systems
- 3.1.1.3 Dynatronics
- 3.1.1.4 Empi/DJO
- 3.1.1.5 Neuro Resource Group
- 3.1.1.6 RS Medical
- 3.1.1.7 Zynex Medical
- 3.1.2 Market Analysis
- 3.1.3 Competitive Analysis
- 3.2 Other Noninvasive Electrical Stimulation Technologies
- 3.2.1 Transcranial Magnetic Stimulation/Other Magnetic Stimulation
- 3.2.1.1 Neuralieve
- 3.2.1.2 The Magstim Company
- 3.2.1.3 Neotonus
- 3.2.1.4 Neuronetics
- 3.2.1.5 Nexstim
- 3.2.2 Electrotherapy Technologies
- 3.2.2.1 Innovative Neurotronics/Hanger Orthopedic Group
- 3.2.2.2 Moeller Medical
- 3.2.2.3 Zynex Medical
- Exhibit 3-1: 2010, Selected Conditions That May Be Treated Using
Transcutaneous Electrical Nerve Stimulation
- Exhibit 3-2: Dynatronics' Sympathetic Therapy Systems
- Exhibit 3-3: Zynex Medical' s Transcutaneous Electrical Nerve Stimulation
Systems
- Exhibit 3-4: 2010, Selected Transcutaneous Electrical Nerve Stimulation
Devices
- Exhibit 3-5: Transcutaneous Electrical Nerve Stimulators, Market Forecast,
2009-2014
- Exhibit 3-6: 2009, Transcutaneous Electrical Nerve Stimulators Market,
Share by Supplier
- Exhibit 3-7: 2010, Selected Transcranial and Other Magnetic Stimulation
Systems
- Exhibit 3-8: Innovative Neurotronics' WalkAide
4. Company Profiles
- 4.1 Advanced Bionics Corporation/Sonova Holding AG
- 4.2 Apnex Medical, Inc.
- 4.3 BioMedical Life Systems, Inc.
- 4.4 Boston Scientific Corporation
- 4.5 Cochlear LTD
- 4.6 Cyberonics, Inc.
- 4.7 DJO, Inc.
- 4.8 Dynatronics Corporation
- 4.9 EnteroMedics, Inc.
- 4.10 MED-EL Corporation
- 4.11 Medtronic, Inc.
- 4.12 RS Medical, Inc.
- 4.13 Second Sight Medical Products, Inc.
- 4.14 St. Jude Medical, Inc.
APPENDIX: COMPANY LISTING
|
